These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 36863689)
1. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma. Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689 [TBL] [Abstract][Full Text] [Related]
2. Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy. Weng J; Wang Z; Hu Z; Xu W; Sun JL; Wang F; Zhou Q; Liu S; Xu M; Xu M; Gao D; Shen YH; Yi Y; Shi Y; Dong Q; Zhou C; Ren N Cancer Res; 2024 Jun; 84(11):1817-1833. PubMed ID: 38484085 [TBL] [Abstract][Full Text] [Related]
3. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519 [TBL] [Abstract][Full Text] [Related]
4. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12. Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice. Huang W; Chen Z; Zhang L; Tian D; Wang D; Fan D; Wu K; Xia L Gastroenterology; 2015 Oct; 149(4):1053-67.e14. PubMed ID: 26065367 [TBL] [Abstract][Full Text] [Related]
6. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089 [TBL] [Abstract][Full Text] [Related]
7. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. Xie P; Yu M; Zhang B; Yu Q; Zhao Y; Wu M; Jin L; Yan J; Zhou B; Liu S; Li X; Zhou C; Zhu X; Huang C; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Guo L; Li H J Hepatol; 2024 Jul; 81(1):93-107. PubMed ID: 38403027 [TBL] [Abstract][Full Text] [Related]
8. Exosomal DLX6-AS1 from hepatocellular carcinoma cells induces M2 macrophage polarization to promote migration and invasion in hepatocellular carcinoma through microRNA-15a-5p/CXCL17 axis. Wang LP; Lin J; Ma XQ; Xu DY; Shi CF; Wang W; Jiang XJ J Exp Clin Cancer Res; 2021 May; 40(1):177. PubMed ID: 34039401 [TBL] [Abstract][Full Text] [Related]
9. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice. Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627 [TBL] [Abstract][Full Text] [Related]
10. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560 [TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
12. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related]
13. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8 Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979 [TBL] [Abstract][Full Text] [Related]
14. Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion. Yang J; Xing Z Exp Biol Med (Maywood); 2021 Sep; 246(17):1928-1937. PubMed ID: 34053234 [TBL] [Abstract][Full Text] [Related]
15. SRSF10 facilitates HCC growth and metastasis by suppressing CD8 Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691 [TBL] [Abstract][Full Text] [Related]
16. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791 [TBL] [Abstract][Full Text] [Related]
17. HMGA1 Promotes Macrophage Recruitment via Activation of NF- Chen J; Ji K; Gu L; Fang Y; Pan M; Tian S J Immunol Res; 2022; 2022():4727198. PubMed ID: 35785026 [TBL] [Abstract][Full Text] [Related]
18. Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization. Xu W; Weng J; Xu M; Zhou Q; Liu S; Hu Z; Ren N; Zhou C; Shen Y Cancer Immunol Immunother; 2024 Feb; 73(3):56. PubMed ID: 38367070 [TBL] [Abstract][Full Text] [Related]
19. TRIM65 knockout inhibits the development of HCC by polarization tumor-associated macrophages towards M1 phenotype via JAK1/STAT1 signaling pathway. Jiang M; Wang D; Su N; Lou W; Chen Y; Yang H; Chen C; Xi F; Chen Y; Deng L; Tang X Int Immunopharmacol; 2024 Feb; 128():111494. PubMed ID: 38218012 [TBL] [Abstract][Full Text] [Related]
20. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]